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Tyrosine kinase inhibitors (TKIs) which target angiogenesis are promising treatments for patients with metastatic medullary and
diﬀerentiated thyroid cancers. Sorafenib, sunitinib, and pazopanib are commercially available drugs which have been studied in
these diseases. Vandetanib is the ﬁrst drug approved in the United States for treatment of medullary thyroid cancer. These TKIs are
used as chronic therapies, and therefore it is imperative to understand the adverse event proﬁle in order to avoid excessive toxicity
and maintain patients on therapy as long as it proves beneﬁcial. Here we review common toxicities, management of these, and
other challenging situations that arise when using TKIs in patients with thyroid cancer.
1.Introduction
Thyroid cancer is now the 5th most commonly diagnosed
cancer in women and 9th in overall incidence in the United
States; however, fewer than 2000 people die per year of
their disease and mortality rates have remained fairly stable
for the past several decades [1]. The most common form
of thyroid cancer, diﬀerentiated thyroid cancer (DTC), is
derivedfromthefollicularcellsofthethyroid,anditincludes
papillary and follicular thyroid cancers. While most patients
are cured or have indolent disease, a small percentage
develop metastases that no longer respond to treatment with
radioactive iodine or TSH suppressive therapy. Medullary
thyroid cancer (MTC) accounts for only about 2-3% of
thyroid cancers and is derived from the neuroendocrine “C”
cells of the thyroid gland. The only treatment with curative
intent for medullary thyroid carcinoma is complete surgical
resection.
Therapy with tyrosine kinase inhibitors (TKIs) has only
recently been studied in thyroid cancer. The discovery that
BRAF (in papillary and anaplastic thyroid cancers) and
RET (in MTC) mutations, as well as angiogenesis, play a
signiﬁcant role in tumorigenesis in DTC and MTC led to
several clinical trials over the past decade with multikinase
inhibitors. For purposes of this paper, TKIs refer to small
molecule drugs, which target multiple pathways, including,
but are not limited to, vascular endothelial growth factor
receptor (VEGFR). Sorafenib, sunitinib, and pazopanib
are three commercially available TKIs which have shown
f a v o r a b l er e s u l t si np h a s eI It r i a l si nD T C[ 2–4]. Although
these small trials have reported favorable responses, at this
time, there are no published results of large phase III trials in
DTC. Favorable results of a phase III, randomization study
of vandetanib versus placebo in MTC have been reported
[5]; however, it is important to note that patients on this
study were not required to have progressive disease prior to
study entry. Vandetanib was recently approved by the Food
and Drug Administration for symptomatic or progressive
MTC, establishing it as the ﬁrst drug to be approved for this
disease. The drug is available only through the Vandetanib
Risk Evaluation and Mitigation Strategy (REMS) Program
duetotheprolongationoftheQTintervalandreportedcases
of torsades de pointes and sudden death in clinical trials.
Sorafenib has also been studied in MTC in a phase II trial
[6], and encouraging results of sunitinib in MTC have been
presented at a national meeting [7].2 Journal of Thyroid Research
Table 1: Major adverse events associated with commercially available TKIs which have been studied in thyroid cancer.
Adverse event Sorafenib (%) Sunitinib (%) Pazopanib (%) Vandetanib (%)
All-grade ≥grade 3 All-grade ≥grade 3 All-grade ≥grade 3 All-grade ≥grade 3
Hypertension 17 4 30 12 40 4 33 9
CHF or LVEF decline 1.7 NR 13 3 <1% NR <1N R
Proteinuria NR NR NR NR 9 <11 0 0
Hand-foot skin reaction 3 0 62 966 N R N R N R
Stomatitis NR NR 30 1 4 NR NR NR
Anorexia 16 <13 4 22 222 14
Weight loss 10 <11 2<15 2 3 . 5 1 01
Diarrhea 43 2 61 9 52 3.5 57 11
AST elevation NR NR 56 2 53 7.5 NR NR
ALT elevation NR NR 51 2.5 53 12 51 2
Fatigue 37 5 54 11 19 2 24 6
Hypothyroidism NR NR 14 2 7 NR NR NR
Arterial thromboembolism 2 . 9N RN RN R3 2N R N R
Hemorrhage/bleeding (all sites) 1 5 33 03 1 3 2 N R N R
CHF: congestive heart failure; LVEF: left ventricular ejection fraction; AST: aspartate aminotransferase; ALT: alanine aminotransferase; NR: notr e p o r t e d .
Data extracted from the phase 3 trials or from the prescribing drug reference information [9, 28–30].
Table is adapted from [31].
There are many challenges posed by the use of TKIs,
which we believe should be used with caution and reserved
for patients with either advanced, progressive disease or
bulky disease which may compromise organ function. This
review focuses on highlighting the most common and prob-
lematic adverse events associated with TKIs with suggestions
formanagement.Otherdilemmasthatoftenarisewithuseof
these drugs will be described as well.
2. AdverseEventManagement
Although TKIs are generally better tolerated than cytotoxic
chemotherapy, many patients develop side eﬀects from on-
target and oﬀ-target eﬀects which require aggressive man-
agement in order to maintain patient compliance, optimize
therapy, and avoid potentially life-threatening consequences.
Since many patients require long-term use of TKIs for
continued control of disease, it is imperative for the treating
clinician to be familiar with the potential side eﬀects of
these drugs. The most frequent side eﬀects of TKIs are
hypertension, dermatologic eﬀects, fatigue, and diarrhea.
In addition, the risk of bleeding and liver toxicity may
be fatal. The clinician should conduct thorough physical
and laboratory examinations prior to considering therapy
with these drugs to identify the most appropriate choice of
treatment and must monitor and treat adverse events during
therapy. Treatment of all comorbid conditions should be
optimized and drug-drug interaction, antifungals, antiemet-
ics, and class III antiarrhythmic agents avoided to prevent
interactions with TKIs. In this section we will discuss the
most common and potentially fatal side eﬀects of TKIs with
management recommendations.
Table 1 lists adverse events of the commercially available
TKIs relevant to thyroid cancer, their incidence, and grades
(data extracted from phase III trials in renal cell carcinoma
and package inserts) using Common Terminology Criteria
for Adverse Events version 3.0 (CTCAE v3.0). The CTCAE
is a list of descriptive terminology utilized for adverse event
grading and reporting on clinical trials and is made available
through the CTEP website at http://ctep.cancer.gov/proto-
coldevelopment/electronic applications/docs/ctcaev3.pdf.
2.1. Drug-Drug Interactions. Cytochrome P450 enzymes,
expressed primarily in the liver, play a primary role in the
metabolism of many drugs. Sunitinib, sorafenib, pazopanib,
and vandetanib are all metabolized by cytochrome P450
3A4 (CYP3A4). Of the four drugs, sorafenib appears to
be the least susceptible to CYP3A4 inducers or inhibitors,
although the package labeling warns against concomitant
use of CYP3A4 inducers [8]. Concomitant use of CYP3A4
inducers may decrease the plasma concentration of the TKI,
resulting in decreased eﬃcacy, while inhibitors may increase
the plasma concentration, resulting in toxicity. Itraconazole,
a potent inhibitor of CYP3A4, does not appear to aﬀect
the metabolism of vandetanib [9]. Table 2 lists the more
common, clinically signiﬁcant drugs metabolized via the
CYP3A4 enzyme system.
The medical history should include a thorough review
of medications which may aﬀect the metabolism of the
TKI. Concomitant drugs which are metabolized via CYP3A4
should be avoided or substituted for another drug. If
a CYP3A4 inhibitor drug cannot be eliminated, a dose
reduction in the TKI should be considered. Patients should
also be monitored for increasing side eﬀects if a CYP3A4
inhibitor is coadministered.
2.2. Cardiovascular. Hypertension is the most common car-
diovascular side eﬀect associated with antiangiogenic drugs.Journal of Thyroid Research 3
Table 2: Clinically signiﬁcant CYP3A4 inducers, inhibitors, and substrates.
CYP3A4 inducers CYP3A4 inhibitors CYP3A4 substrates
Dexamethasone Calcium channel blockers: amiodarone,
verapamil
Statins: atorvastatin, lovastatin, and
simvastatin (not pravastatin) (not
rosuvastatin)
Anticonvulsants: phenytoin,
carbamazepine
Azole antifungals: itraconazole, voriconazole,
and ketoconazole
Calcium channel blockers: amlodipine,
diltiazem, felodipine, nifedipine, and verapamil
Phenobarbital
Rifampin Macrolide antibiotics: erythromycin, and
clarithromycin (not azithromycin)
St. John’s wort
HIV antivirals: nonnucleoside reverse
transcriptase inhibitors: efavirenz, and
nevirapine
HIV antivirals: protease inhibitors: indinavir,
nelﬁnavir, and ritonavir
Pioglitazone
The mechanism of hypertension is not well understood,
b u ti th a sb e e ns u g g e s t e dt h a ti ti sd u et oi n c r e a s e dﬂ u i d
retention, endothelial dysfunction, nitrous oxide inhibition,
rarefaction [10], reduction of vascular surface area, and
increase in peripheral vascular resistance caused by inhibi-
tion of angiogenesis [11–14]. A recent study by Rini et al.
suggests that the rise in blood pressure above 140/90 may
be a biomarker for anticancer therapy and was associated
with signiﬁcant survival beneﬁt even with treatment of
antihypertensives. The use of antihypertensives did not
reduce the eﬃcacy of sunitinib in metastatic renal cell
carcinoma [15].
Theonsetofhypertensionisvariable.Bloodpressuremay
begin to rise within days of therapy prior to steady state
or the onset of the therapies’ biological eﬀects or may be
more indolent. There are no clear guidelines for managing
TKI-induced hypertension. It is our clinical practice to
use ACE inhibitors, angiotensin receptor blockers (ARBs)
or a beta blocker as ﬁrst-line therapy for hypertension
since these drugs are not metabolized via the CYP3A4
enzyme system. However, the choice of an antihypertensive
should be individualized. The Angiogenesis Task Force of
the National Cancer Institute Investigational Drug Steering
Committee recently published guidelines for management
of hypertension with TKIs [16]. Hypertension should be
controlled based on compelling and noncompelling indi-
cations to a goal of <140/90 prior to starting TKIs. Once
a TKI is initiated, patients should have the blood pressure
monitored within 1 week. Blood pressure monitoring at
home may be more eﬀective at prediction of outcomes from
cardiovascular disease than clinic blood pressure monitoring
[17]. If the blood pressure is above goal, antihypertensive
therapy should be initiated or adjusted. Patients should
continue to check their blood pressure daily (with brachial
blood pressure device) and report results on a weekly basis
(until adequate blood pressure control is achieved), and
antihypertensive drugs should be rapidly titrated or new
drugs added to the regimen. Once control of blood pressure
is obtained, the blood pressure should be monitored on a
monthly basis. Interruption or dose reduction of the TKI
maybenecessaryinordertoachieveadequatebloodpressure
control. Some calcium-channel blockers, such as felodipine,
diltiazem, nifedipine, and verapamil, are CYP3A4 substrates
or inhibitors and should be avoided.
Sunitinib and pazopanib can lead to QT interval pro-
longation; therefore, they should be used with caution in
patients with a history of QT prolongation and patients
taking antiarrhythmic drugs. Torsade de pointes was seen
in <0.1% of patients exposed to sunitinib and <2% of
patients treated with pazopanib. Vandetanib carries a black
box warning due to QT interval prolongation, Torsade
de pointes, and sudden death observed in clinical trials
involving patients with a broad variety of solid malignancies.
Serial monitoring of electrocardiograms and electrolytes is
mandated and electrolyte abnormalities should be corrected
[9, 18, 19]. In a phase III trial that examined the eﬃcacy and
safety of vandetanib 300mg in the treatment of unresectable
locally advanced or metastatic MTC, QT prolongation was
reported in 14% of patients randomized to vandetanib
and in 1% of patients randomized to placebo, with 8%
(18/231) and 1% (1/99), respectively, being ≥grade 3 events.
Vandetanib should not be given to patients who have a
historyofTorsadesdepointes,congenitallongQTsyndrome,
bradyarrhythmias, or uncompensated heart failure. Vande-
tanib should not be started in patients whose corrected QT
interval (QTcF, Fridericia formula) is greater than 450ms.
Speciﬁc guidelines for monitoring of QT abnormalities and
electrolytes in patients taking vandetanib are speciﬁed in the
package insert [9]. In addition, use of concomitant drugs
known to prolong the QT interval, such as amiodarone and
erythromycin, should be avoided.
A less common but serious adverse event associated
with TKIs is systolic and diastolic congestive heart failure.
It appears to be more common with sunitinib but has
been reported with sorafenib and pazopanib. Patients may
present with very dramatic symptoms of heart failure, while
others demonstrate mild symptoms which may be diﬃcult
to diﬀerentiate from fatigue due to the TKI or the tumor
itself [20]. Cardiac toxicity, although not always completely
reversible, is often a manageable condition if patients have4 Journal of Thyroid Research
careful monitoring and treatment with routine heart failure
therapies with beta blockers and ACE inhibitors/ARB as rec-
ommended by the guidelines of heart failure management by
theAmericanCollegeofCardiology.Theetiologyoftheheart
failureisthoughttobeduetodirectreversiblecardiomyocyte
toxicity, possibly exacerbated by hypertension which may
progress to irreversible, progressive injury if not treated
with standard heart failure therapy [21]. This toxicity is not
completely understood, but platelet-derived growth factor
receptor-β (PDGFR-β) inhibition has been implicated as
playing a role in the response to pressure-overload-induced
stress [22]. We recommend that all patients initiating TKIs
have a baseline echocardiogram and periodic monitoring
while they are on therapy. Furthermore, aggressive man-
agement of hypertension may help reduce cardiomyocyte
damage.
Case Number 1. A 69-year-old woman with a history of
hypertension and premature ventricular contractions was
referred to our center. She had a history of T4a, N0,
M0, stage IVA papillary thyroid cancer for 10 years prior.
The patient’s thyroid cancer was initially managed with
total thyroidectomy and radioactive iodine ablation, but
she developed local recurrence and pulmonary metastases
several years later. She continued to have progressive disease
in the lungs and neck and was referred to our center. The
patient was enrolled into a phase II clinical trial with an
investigational TKI targeting VEGFRs, PDGFR, and others.
The patient’s blood pressure was normal prior to initiation
of the investigational TKI, but one week later she devel-
oped grade 2 hypertension which was diﬃcult to control
despite treatment with multiple antihypertensive agents.
Her pretreatment echocardiogram demonstrated an ejection
fraction of 55–60%. Nearly 4 months after starting on the
investigational agent, she underwent adenosine stress test
which identiﬁed a 30% ejection fraction with hypokinesia
in the anterior septal segments which partially reversed
with rest. Because of the presence of a left bundle branch
block at baseline, deﬁnitive diagnosis of ischemia was not
possible from the images. Carvedilol was initiated, and the
investigational TKI was held. Echocardiogram conﬁrmed
the low ejection fraction. A cardiac catheterization with
myocardial biopsy was performed. She was found to have
mildischemicheartdisease(deﬁnedaslessthan50%stenosis
inanycoronary)whichwasdisproportionatetoherdegreeof
heart failure, and therefore the heart failure was attributed
to the TKI. Direct cardiomyocyte toxicity was conﬁrmed
with the biopsy, demonstrating hypertrophy and interstitial
edema, increased lipid droplets, and dilatation of sarcotubu-
lar elements (Figure 1). Since the biopsy showed no myocyte
death (indicating reversibility) and the echocardiogram
showed a return to baseline, after 3 weeks, the investigational
agent was reintroduced at a reduced dose. Two months
later she was found to have progression of disease, and the
investigational agent was discontinued permanently.
2.3. Renal. Proteinuria associated with antiangiogenic ther-
apies was ﬁrst described with bevacizumab, a monoclonal
5µm
Figure 1: Transmission electron micrographs of endomyocardial
biopsy from patient with systolic heart failure treated with a TKI.
Section shows hypertrophy and interstitial edema with edematous
mitochondria (open red arrow), with increased lipid droplets (solid
red arrow) and dilatation of sarcotubular elements (yellow arrow).
These ﬁndings are consistent with acute but reversible injury.
antibody against VEGF [23]. Small-molecule tyrosine kinase
inhibitors, which inhibit VEGF-R, lead to proteinuria as
well[24].Thromboticmicroangiopathyandacuteinterstitial
nephritis have been reported with sorafenib and sunitinib
[25, 26]. The glomerular podocytes express VEGF, and
glomerular endothelial cells express VEGF receptors. Thus,
a proposed mechanism of proteinuria is that deletion of
VEGF allele in podocytes or inhibited VEGF signaling leads
to proteinuria and capillary endotheliosis [27].
All patients who will receive antiangiogenic therapies
should have a baseline urinalysis and protein to creatinine
ratio, with routine monitoring for development of pro-
teinuria while on treatment. A urine protein to creatinine
ratio of ≥1 or 24-hour urine with ≥1gram/dL/24 hours
of protein should prompt intervention. The decision to
hold drug should be considered on a case-by-case basis.
Treatment with an ACE inhibitor or ARB should be initiated
and consultation with nephrology may be warranted. As
proteinuria is a class eﬀect of antiangiogenic treatments,
changing from one agent to another may not prevent this
eﬀect in a patient.
2.4. Dermatologic. Dermatologic reactions observed with
TKIs include hand-foot syndrome (HFS), skin induration
or callous formation, rash, alopecia, hair texture and color
changes, and skin discoloration. HFS, the most common and
potentially most debilitating dermatologic eﬀect, presents
as desquamating lesions in a palmoplantar distribution
typicallyatpressurepointsorareasoffrictionortrauma.The
lesions can signiﬁcantly aﬀect a patient’s quality of life, thusJournal of Thyroid Research 5
Table 3: Suggested dose modiﬁcation for skin toxicity for sorafenib [8].
Skin toxicity grade Occurrence Suggested dose modiﬁcation
Grade 1: numbness, dysesthesia, paresthesia, tingling,
painless swelling, erythema or discomfort of the hands
or feet which does not disrupt the patient’s normal
activities
Any occurrence Continue sorafenib and consider topical
therapy for symptomatic relief
Grade 2: Painful erythema and swelling of the hands or
feet and/or discomfort aﬀecting the patient’s normal
activities
1st occurrence
Continue sorafenib and consider topical
therapy for symptomatic relief. If no
improvement within 7 days, see below
No improvement within 7
days or 2nd or 3rd occurrence
Interrupt sorafenib until toxicity resolves
to grade 0-1. When resuming treatment,
decrease sorafenib dose by one dose level
(400mg daily or 400mg every other day)
4th occurrence Discontinue sorafenib treatment
Grade 3: Moist desquamation, ulceration, blistering or
severe pain of the hands or feet, or severe discomfort
that causes the patient to be unable to work or perform
activities of daily living
1st or 2nd occurrence
Interrupt sorafenib until toxicity resolves
to grade 0-1. When resuming treatment,
decrease sorafenib dose by one dose level
(400mg daily or 400mg every other day)
3rd occurrence Discontinue sorafenib treatment
necessitating drug discontinuation or dose reduction. The
pathogenesis of HFS is not entirely clear. Preventive appli-
cation of hand and foot lubricants should be implemented
at time of drug initiation. The package insert for sorafenib
gives clear recommendations on dose modiﬁcations and
holds for skin toxicity (Table 3). It has been the authors’
experience with sorafenib that when patients develop grade
≥3 HFS, drug interruption until skin toxicity declines to
grade ≤1 with reinitiation at 200mg daily, and titration
by 200mg every 3–5days can prevent further escalation of
skintoxicity(unpublisheddata).Stevens-Johnsonsyndrome,
characterized by a prodrome of malaise and fever, followed
by rapid development of erythematous or purpuric macules,
which can progress to epidermal necrosis or sloughing,
has been reported with vandetanib. A patient with these
signs and/or symptoms should discontinue drug therapy
immediately and seek medical attention, as this could be a
life-threatening adverse eﬀect.
Skin induration and callous formation can lead to pain
at pressure points and limit mobility. Referral to podiatry
can be considered to reduce callous size. Skin evaluation for
development of actinic keratoses or keratoacanthoma-type
squamous cell carcinomas (KA-SCC) should be performed
regularly while being treated with sorafenib and BRAF
inhibitors, as these lesions have been described primarily
with targeted therapy against Raf kinase or mutant BRAF
[32–35]. These lesions can develop as solitary or multiple
lesions, weeks to months after starting drug therapy, and
do not need to be conﬁned to sun-exposed areas. Fortu-
n a t e l y ,K A - S C Ch a sn o tb e e nr e p o r t e dt om e t a s t a s i z e ,a n d
spontaneous regression has been reported [32]. KA-SCCs
should be completely excised. It has not been uniformly
recommended that drug discontinuation occur when KA-
SCCs develop due to the low metastatic potential; however,
patients should be made aware of this eﬀect and maintain
routine skin evaluations.
2.5. Gastrointestinal System. Diarrhea, nausea, mucositis,
stomatitis, dysgeusia, anorexia, abdominal discomfort, and
weight loss may develop with the use of these drugs.
Reduced side eﬀects may occur if medication is taken with
a large meal and water, if appropriate for administration
per package insert. Appropriate use of supportive therapies
with antidiarrheal or antiemetic medications may prevent
the need for dose reduction or discontinuation. In the
case of severe, unresponsive gastrointestinal eﬀects, drug
discontinuation should be implemented and reinitiated at a
reduced dose once symptoms resolve to baseline or grade 1
level. Gastrointestinal perforation or ﬁstula development is a
rare, but potentially life-threatening, adverse event reported
with TKIs. Risk factors include underlying tumor at perfora-
tion, diverticulitis, bowel obstruction, recent sigmoidoscopy
or colonoscopy, and historical abdominal/pelvic irradiation
[36]. Drug discontinuation is warranted if perforation event
occurs.ConsiderationforadiﬀerentTKIwillneedtobedone
with caution.
Hepatic toxicity or abnormalities, demonstrated by ele-
vations in aspartate aminotransferase (AST) and alanine
aminotransferase (ALT) and bilirubin, can occur. Eleva-
tions in AST or ALT were the most common metabolic
abnormality requiring treatment seen in the phase III
trial of pazopanib in renal cell carcinoma [28]. Although
isolated elevations of total bilirubin were also seen at a
similar frequency, concurrent elevations of ALT and total
bilirubin were rare. The presence of a polymorphism in the
uridinediphosphateglucuronosyltransferase1A1(UGT1A1)
gene, which predisposes to Gilbert’s syndrome, leads to
reduced enzymatic activity necessary for the conjugation
of bilirubin allowing it to be excreted in bile. Xu et al.
reported that the presence of a polymorphism in UGT1A1
was signiﬁcantly associated with pazopanib-induced hyper-
bilirubinemia, indicating that isolated unconjugated hyper-
bilirubinemia was a benign ﬁnding associated with Gilbert’s6 Journal of Thyroid Research
syndrome, which did not require discontinuation of drug
therapy [37]. Conjugated hyperbilirubinemia would require
further investgation. None of the genetic markers evaluated
in this study were associated with hepatic transaminase
elevation, thus leaving the etiology still to be determined.
TKIs can lead to asymptomatic increases in pancre-
atic enzymes or rarely acute pancreatitis, most commonly
reported with sorafenib and pazopanib. Standard treatment
for pancreatitis and evaluation with endoscopic ultrasonog-
raphy and other diagnostic testings for underlying causes
of pancreatitis should be implemented. However, radiologic
evidence of pancreatic damage or pancreatitis often is not
found. Thus, dose-limiting toxicity for pancreatic enzyme
elevation should be applied to grade 4 levels associated with
clinical ﬁndings of pancreatitis, or if considered to be life
threatening[38].Thecauseofelevationinamylaseandlipase
is unclear, although some have attributed it to pancreatic
ischemia from antiangiogenesis or to other drug-related
eﬀects.
2.6. Hematologic. Mucosal bleeding (e.g., epistaxis) to hem-
orrhage (i.e., gastrointestinal, pulmonary, cerebral, vaginal)
has been reported with TKIs. Although mild mucosal
bleeding could be attributed to inhibition of VEGFR-2
causing microvascular leaks from endothelial cell damage,
clinically more severe hemorrhage is attributed to tumoral
invasion of large vessels or other concurrent pathological
conditions[36].Additionally,thrombosishasbeenidentiﬁed
with TKI use. Inhibition of VEGF signaling could lead
to overproduction of erythropoietin in the liver, which
increases hematocrit and blood viscosity [39, 40]. Addi-
tionally, as wound healing is dependent upon angiogenesis,
VEGF-inhibitors can impair or delay wound healing after
surgery or other invasive procedures. Thus, drug should be
withheld before and after surgery to optimize wound healing
[36].
Hematologic laboratory abnormalities with neutropenia,
lymphopenia, and thrombocytopenia are associated with
TKIs. In contrast, anemia occurs less frequently, which may
be explained by the relative increased erythrocytosis seen
with this class of drugs. As patients with diﬀerentiated
thyroid carcinoma may have received large cumulative doses
of radioactive iodine and thyroid cancer patients may have
received external beam radiation therapy, myelosuppression
may be present prior to TKI initiation. Thus, routine
monitoring of complete blood count and diﬀerential is
required while on therapy.
2.7. Miscellaneous. Hypothyroidism or rising thyroid stimu-
lating hormone (TSH), requiring increasing the thyroid hor-
mone replacement doses, is seen as a class eﬀect. Suggested
etiologies have been poor absorption of levothyroxine from
concomitant treatment-related diarrhea, or in patients with
intact thyroid glands, regression of thyroid capillaries, or
inhibition of thyroid peroxidase [36, 41]. Thyroid function
should be monitored routinely while on TKI treatment to
maintain a suppressed TSH in patients with DTC and a
normal TSH in MTC patients.
Fatigue is a pervasive and often diﬃcult-to-manage
problem in cancer patients and may be related to many
factors,inadditiontodirecttoxicityoftargeteddrugtherapy.
Investigation for causes (e.g., anemia, hypothyroidism, car-
diac dysfunction, renal dysfunction) should be performed.
Supportive care with adequate nutrition, exercise, and stress
reducing techniques is encouraged.
3. Recommendations for Dose Modiﬁcations or
Discontinuation of TKIs due to Intolerance
NonhematologicAdverseEvents(AEs). Patientswithtolerable
grade 1-2 nonhematologic AEs may continue TKI therapy
while treatment for the AE is being optimized. For example,
grade 1–3 hypertension does not necessarily require a dose
modiﬁcationordrugholdifthepatientcanbemanagedwith
antihypertensive agents. On the other hand, adverse events
such as grade 1-2 skin rash, which have minimally eﬀective
treatmentsand/oraredistressful orembarrassing topatients,
may require drug interruptions. Although the package insert
for sorafenib describes dose modiﬁcation recommendation
for cutaneous toxicity [8]( Table 3), others do not have
clearly deﬁned dose modiﬁcations for this toxicity. Recurrent
grade 2 AEs require drug hold and often dose reduction if
they are possibly related to the TKI and not responding to
optimal supportive therapy. However, since TKIs are often
chronic treatments for patients with thyroid cancer, the
decision to hold and reduce the dose is often dictated in
part by the patient’s quality of life and physician judgment.
Most grade 3 toxicities will require a drug hold until the
AE improves signiﬁcantly with resumption of the TKI at
a reduced dose. However, grade 3 toxicities which can be
readily managed (such as correction of hypokalemia arising
from diarrhea which can be controlled) do not require a
drug hold. Second occurrence of grade 3 toxicity should
be managed again with drug hold and reduction of the
dose.Thirdoccurrenceswhichcannotbeeﬀectivelymanaged
often require discontinuation of the TKI. Grade 4 AEs are
life-threatening events, and if related to the TKI, require
discontinuation of drug. However, in some select cases, it
may be appropriate to resume treatment after reduction of
the dose by two dose levels and if other interventions are
implemented to prevent recurrence of the event. Thus, the
decision to resume drug in patients with manageable grade
4 AEs, even when drug related, must be individualized and
the beneﬁt/risk ratio should be considered. Careful review
of concomitant medications and herbal remedies which may
cause increases in the drug levels of the TKI should also be
given consideration.
Hematologic Adverse Events. Grade 2 hematologic toxicities
do not require dose reduction. Grade 3-4 neutropenia
and thrombocytopenia and grade 4 anemia require dose
reductions upon ﬁrst and second occurrences. Grade 3 and
4 hematologic toxicities are rare in thyroid cancer patients
receiving TKIs; thus, other causes such as myelodysplasia
should be ruled out.Journal of Thyroid Research 7
Intolerance to TKIs. The deﬁnition of intolerance, proposed
by Jabbour et al. in the context of leukemia, is met if
the patient has one or more criterion as delineated in the
manuscript [19]. We propose the following modiﬁed criteria
as a deﬁnition of TKI intolerance: presence of one or more
of the following criteria: (i) any grade 3-4 non-hematologic
toxicity related to TKI therapy that has recurred despite
dose reduction and optimal symptomatic measures, (ii) any
grade 2 non-hematologic, intolerable toxicity, related to TKI
therapy, that persists for more than a month despite optimal
supportive measures, or (iii) grade 3-4 hematologic toxicity,
related to TKI therapy, that is unresponsive to supportive
measures and would require dose reductions below the
accepted minimal eﬀective dose, (iv) any life-threatening
grade 4 non-hematological toxicity related to TKI therapy.
4. Variable Responses in Different Tissues
Case Number 2. A 54-year-old man with a history of stage
IV papillary thyroid carcinoma was seen at our institu-
tion. He developed progressive disease that was noted to
be nonavid to radioactive iodine. He was initiated on a
clinical trial investigating a TKI in metastatic progressive
thyroidcarcinoma.Hedevelopedanexcellentresponse(48%
decrease in target lesion by RECIST), but his spinal bone
metastasis continued to progress and became symptomatic
(Figures 2(a) and 2(b)). His TKI therapy was held, and
his progressive bone lesion was treated with external beam
radiation. Due to overall favorable response in soft tissues,
the TKI was restarted. The patient is still on therapy 24
months later with stabilization of disease in his bone and soft
tissue lesions.
This case illustrates two points. First, tumor regression in
response to TKI therapy can occur in some organs but not
in other areas in the same patient. Additionally, TKI therapy
can be continued in a patient with diﬀerential responses in
various organs provided that local therapy is initiated for the
region of progressive disease. This case is not unique; this
scenario of varying responses to therapy in diﬀerent organs
is often encountered in metastatic thyroid cancer patients
treated with TKI therapy. For example, lung metastases
respond more favorably to sorafenib and sunitinib than do
bone or pleura [42]. It has been noted that TKIs may lead
to varying responses in diﬀerent tissue sites in other cancers
as well [43] and that continuation of systemic therapy after
appropriate local therapy could be beneﬁcial [44]. This
diﬀerential response may not be unique to TKIs [45]. The
pathophysiologic mechanism behind this variable response
is not well elucidated. Some theories include host, tumor,
and stroma factors. Resistance to TKI therapy has proven
mechanisms in tumor and stroma as well. Some postulated
theories include varying hepatocyte growth factor (HGF),
VEGF receptors or serum levels, decreased drug bioavailabil-
ity in certain organs, and organ-speciﬁc tumor resistance.
Until mechanisms are better elucidated to direct therapy
for organ-speciﬁc TKI selection, consideration should be
given to local therapies for areas of progressive disease.
Clinically, one should consider irradiating bone lesions
Pre-treatment
(a)
Post-treatment
(b)
Figure 2: Patient with partial response in lymph nodes but
progression in bone. CT scans before (a) and after (b) 6 months
of therapy with a TKI. The patient had a partial response in
mediastinal and hilar adenopathy but progression in bone with
cortical destruction. The patient’s bone lesions were irradiated, and
he was restarted on the TKI. The patient continues on the TKI after
24months and has no further evidence of progression.
(especially if symptomatic) if they progress on TKI therapy.
If a bone lesion is threatening vital structures (i.e., the spinal
cord), consideration should be given to treating the bone
lesion prior to TKI therapy. This may avoid a drug hold
later and further compromise of vital structures. In general,
the TKI is held during radiation therapy, although there
are upcoming trials that may inform us diﬀerently. Bony
metastatic lesion may also be treated with bisphosphonates
or denosumab. This may decrease pain in the bony lesions or
may decrease rate of progression, although trials are needed
to determine eﬃcacy of these therapies and frequency of
dosing.
5. SequentialUse of TKIs
Theformerbeliefthatifapatienthasprogressedthroughone
TKI, he/she will fail with another TKI is false and outdated.
Due to the many overlapping targets it was assumed that
there would be complete cross-resistance. There is increasing
evidence that with sequential application of these drugs, a
patient who had progressive disease with one TKI may still8 Journal of Thyroid Research
respond to the next one. In a cohort of metastatic renal cell
carcinoma treated with sunitinib after progression through
sorafenib, the response rate (or eﬃcacy) seen with second-
line sunitinib after sorafenib was similar to that of ﬁrst line
sunitinib [46]. Investigations are under way to determine the
best order for sequential TKI and other targeted therapies.
6. Summary
Drug development in oncology has led to several new
targeted agents which have demonstrated eﬃcacy in pro-
gressive thyroid cancer. Although it was initially thought
that these drugs would prove to be less toxic than cytotoxic
chemotherapy, the fact that these drugs have many oﬀ-
target eﬀects and the likelihood that most patients will be
treated chronically beg the need for further research to
better understand the cause of these toxicities and their
optimal management. It also underscores the importance of
appropriate patient selection.
Patients and physicians must understand the possible
adverse eﬀects and weigh the advantages versus the risks of
these drugs. Alternatives to systemic therapy for localized
disease, such as external beam radiation or embolization
should be considered when appropriate. Until prolongation
of overall survival can be demonstrated with the use of the
drugs, physicians should exercise caution in the selection of
patients to undergo therapy with a TKI.
Finally, more optimal drug selection should be personal-
ized for the individual patient and tumor. Further research
is needed to determine the ideal targeted therapy for an
individual based on the molecular characterization of the
tumor, stroma, and host factors. Future targeted therapy
development may require that the on-target and oﬀ-target
eﬀects may be reengineered to enhance antiangiogenesis
pathways and avoid cardiovascular, renal, and dermatologic
pathways [47].
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